The acquisition of Erie Retina Research, CASExERIE, and Element Erie enhances Lexitas’s capabilities across retina-focused clinical trials, surgical innovation, and advanced ophthalmic imaging services, creating a more fully integrated platform for drug and device development.
This strategic expansion strengthens Lexitas’s position within the ophthalmic research landscape, reinforcing its commitment to advancing retina-focused clinical and scientific innovation.
Strengthening an Integrated Retina Clinical Research Platform
By bringing together clinical research, surgical expertise, and imaging infrastructure, Lexitas is building a more connected and scalable ecosystem for ophthalmic development.
The integration of Erie Retina Research, CASExERIE, and Element Erie enhances the organisation’s ability to support complex retina studies through a unified operational model. This includes improved alignment between clinical trial execution, surgical innovation, and high-resolution imaging analysis.
Advancing Surgical Innovation and Clinical Trial Execution
CASExERIE adds a dedicated focus on surgical innovation and hands-on clinical expertise, supporting the development of advanced retinal procedures and real-world surgical training environments.
Combined with Lexitas’s established clinical research capabilities, this strengthens end-to-end trial execution, particularly in retina-focused therapeutic areas where procedural precision and specialist insight are critical.
Enhancing Ophthalmic Imaging and Data Capabilities
Element Erie expands Lexitas’s advanced imaging and reading centre capabilities, enabling more consistent, high-quality data capture and interpretation across clinical studies.
This enhanced imaging infrastructure supports more robust endpoint analysis in retinal therapeutics, improving the quality and reliability of clinical trial outcomes.
Positioning for Growth in Retinal Therapeutics
As demand for specialised expertise in retinal therapeutics continues to accelerate, this acquisition positions Lexitas to support sponsors with deeper clinical insight, operational execution, and advanced imaging infrastructure across the full development lifecycle.
By integrating these complementary capabilities, Lexitas strengthens its ability to deliver more efficient, data-driven, and scientifically rigorous support for ophthalmic drug and device development.